The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Open accessAbstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)–dependent reduction of α-ketoglutarate (α-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and α-KG. This prevents the oxidative decarboxylation of isocitrate to α-KG, and facilitates the conversion of α-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Gross et al., 2010
In the citing paper
“AML samples with low to undetectable 2HG were subsequently sequenced and determined to be IDH1 and IDH2 wild-type”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“several samples with elevated 2HG were found to have neomorphic mutations at either IDH1 R132 or IDH2 R172 (Gross et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“Enzymatic assays and measurement of 2HG levels in primary AML samples confirmed that these IDH2 R172 mutations result in 2HG elevation (Gross et al., 2010; Ward et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“serum 2HG levels have successfully correlated with IDH1 R132 mutations in AML”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–744 of 744
Li, M., Zhang, H., Wu, X., Yu, M., Yang, Q., Sun, L., Li, W., Jiang, Z., Xue, F., Wang, T. T., et al. (2024) · eLife · doi:10.7554/elife.100406.1
IDH1 regulates human erythropoiesis by eliciting chromatin state reprogrammingPreprint
Li, M., Zhang, H., Wu, X., Yu, M., Yang, Q., Sun, L., Li, W., Jiang, Z., Xue, F., Wang, T. T., et al. (2025) · eLife · doi:10.7554/elife.100406.2
Leucémies aigües myéloïdes avec mutations IDH1/2
Gabellier, L., Bosetta, E., Heiblig, M., & Sarry, J. (2025) · médecine/sciences · doi:10.1051/medsci/2025045
Lysine- R 2HGylation identified as a post-translational modification in R 2HG-elevated cancersPreprint
Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680013
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Chien, K. S., Loghavi, S., Sasaki, K., McCue, D. A., Daver, N. G., Kadia, T. M., Ravandi, F., Short, N. J., Issa, G. C., Bravo, G. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.001
Giambra, V., & Jenkins, C. R. (2011) · Springer eBooks · doi:10.1007/978-94-007-2801-1_13
Chen, J., Yang, J., Wei, Q., Weng, L., Wu, F., Shi, Y., Cheng, X., Cai, X., Hu, C., & Cao, P. (2020) · Figshare · doi:10.6084/m9.figshare.12082356
Watts, J. M., Wang, E. S., Jonas, B. A., Wilson, F. R., Park, J. E., Cope, S. C., Sheppard, A. D., Thomassen, A., de Botton, S., & Cortes, J. E. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03522-6
Polley, K., & Firdous, S. M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04671-4
Tang, Y., Wu, J., Wang, Q., Sun, L.-Y., Su, B., Li, L., Shen, L.-M., Ni, S.-Q., Shi, Q.-L., Li, J., et al. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02074-1
Nibourel, O. (2010) · theses.fr (ABES) · doi:10.70675/a0f6af54zade8z452eza6efz3f822211d048
Rocquain, J. (2010) · theses.fr (ABES) · doi:10.70675/e8009b43z68f2z48ecz8fe4z442a23be8e4d
Erdem, Ş., Haliloğlu, Y., Uslu, İ. N., Houran, M. A., Ulutabanca, H., Vural, A., Erturhan, M. B., Canatan, H., & Eken, A. (2026) · Inflammation Research · doi:10.1007/s00011-026-02223-8
Molecular markers of gliomas : implications for diagnosis and new target therapies
Stefano, A. L. D. (2017) · theses.fr (ABES) · doi:10.70675/de3bc517z8083z4bf5za1b4z9c09b5970230
Etude des longs ARNs non codants dans la leucémie aiguë myéloblastique à caryotype normal
Clara, E. D. (2015) · theses.fr (ABES) · doi:10.70675/95526bc3z936bz46dazaf31z1e92122f4619
Stage-specific changes in the Krebs cycle network regulate human erythroid differentiation
Romano, M. (2018) · theses.fr (ABES) · doi:10.70675/4312681cz0207z4923zb100z879f8a73681c
Etude de la ferroptose dans les leucémies aiguës myéloïdes : nouvelles stratégies thérapeutiques
Birsen, R. (2020) · theses.fr (ABES) · doi:10.70675/45ca3261z22a8z4237z8076zf98342173232
Origin and pronostic impact of intra-leukemic heterogeneity in acute myeloid leukemias
Duchmann, M. (2022) · theses.fr (ABES) · doi:10.70675/74f56644z3676z489bz8e12z27fa072401b7
Zhang, H.-H., Chen, X.-T., Li, S.-Q., Yan, X.-L., Wang, M., Lin, Y., Yuan, Y.-Y., Mao, Y.-Z., Liu, J. Z., & Xu, W. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02988-9
Role of isocitrate dehydrogenase enzyme in brain cancer, with a focus on glioma
Alkhalaileh, L., Essam, Z. M., Ibrahim, M. A., & Al-khalayleh, M. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_96_2026
Tanaka, K., Kobayashi, Y., & Nakamura, T. (2024) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/fbabshtfen
Qi, D.-B., Li, T., Jiang, T., Lu, Y.-B., Sun, K.-Y., Fu, Z.-R., Song, S., & Zhong, L. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.10.003
BindingDB (2014) · UC San Diego · doi:10.7270/q2t72js5
BindingDB Entry 50013577: Discovery and Optimization of 2
BindingDB (2022) · UC San Diego · doi:10.7270/q2ff3x3s
BindingDB (2025) · UC San Diego · doi:10.7270/q2k078tm
Emerging Anti-cancer Targets in Mitochondria
Ježek, P., Smolková, K., Dvořák, A., & Olejár, T. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_10
Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms
Kundranda, M. N., Tibes, R., & Mesa, R. A. (2011) · Springer eBooks · doi:10.1007/978-3-642-24989-1_12
Metabolic Adaptation in Reprogrammed Cancer Cells
Marks, K. M., & Kung, C. K.-H. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_7
Metadata
- Authors
- Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., Dang, L., Fantin, V. R., & Mak, T. W.
- Affiliations
- Agios Pharmaceuticals Incorporated, Cambridge, MA 02139 1
- University Health Network (CA)
- Agios Pharmaceuticals (United States) (US)
- Corresponding author
- Fantin, Valeria R.
- Mak, Tak W.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-08
- Volume
- 207
- Issue
- 2
- Pages
- 339-344
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2822606
- OpenAlex
- W2159731673
- Cited by
- 736
- References
- 23
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 34 · 2023: 35 · 2022: 29 · 2021: 55 · 2020: 40 · 2019: 36 · 2018: 45 · 2017: 51 · 2016: 61 · 2015: 44 · 2014: 49 · 2013: 61 · 2012: 61
- FWCI
- 45.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Agios Pharmaceuticals
- Terry Fox Foundation
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, IDH mutation, acute myeloid leukemia, alpha-ketoglutarate, NADPH-dependent reduction, gain-of-function mutations, cancer metabolism, metabolic biomarkers
- MeSH terms
- Catalysis, Glutarates, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Mutation, NADP, Recombinant Proteins, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
